These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 37316680)

  • 41. Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies.
    Sills GJ
    Ther Adv Neurol Disord; 2023; 16():17562864231191000. PubMed ID: 37655228
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A critical evaluation of fenfluramine hydrochloride for the treatment of Dravet syndrome.
    Schoonjans AS; Ceulemans B
    Expert Rev Neurother; 2022 May; 22(5):351-364. PubMed ID: 33455486
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.
    Guerrini R; Chiron C; Vandame D; Linley W; Toward T
    Epilepsia Open; 2024 Apr; 9(2):689-703. PubMed ID: 38427284
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis.
    Lattanzi S; Brigo F; Trinka E; Zaccara G; Cagnetti C; Del Giovane C; Silvestrini M
    Drugs; 2018 Nov; 78(17):1791-1804. PubMed ID: 30390221
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
    Gil-Nagel A; Falip M; Sánchez-Carpintero R; Abad-Sazatornil MR; Poveda JL; Aibar JÁ; Cardenal-Muñoz E; Aras LM; Sánchez R; Sancho-López A; Trillo-Mata JL; Torrejón M; Gil A
    Epilepsy Behav; 2022 Jul; 132():108711. PubMed ID: 35588562
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cannabidiol use in patients with Dravet syndrome and Lennox-Gastaut syndrome: experts' opinions using a nominal group technique (NGT) approach.
    Bonanni P; Ragona F; Fusco C; Gambardella A; Operto FF; Parmeggiani L; Sartori S; Specchio N
    Expert Opin Pharmacother; 2023 Apr; 24(5):655-663. PubMed ID: 37021712
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
    Chen JW; Borgelt LM; Blackmer AB
    Ann Pharmacother; 2019 Jun; 53(6):603-611. PubMed ID: 30616356
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fenfluramine for the treatment of status epilepticus: use in an adult with Lennox-Gastaut syndrome and literature review.
    Strzelczyk A; Becker H; Tako L; Hock S; Hattingen E; Rosenow F; Mann C
    Neurol Res Pract; 2024 Feb; 6(1):10. PubMed ID: 38383582
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of fenfluramine on seizures and comorbidities in SCN8A-developmental and epileptic encephalopathy: A case series.
    Aledo-Serrano Á; Cabal-Paz B; Gardella E; Gómez-Porro P; Martínez-Múgica O; Beltrán-Corbellini A; Toledano R; García-Morales I; Gil-Nagel A
    Epilepsia Open; 2022 Sep; 7(3):525-531. PubMed ID: 35802036
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients.
    Schoonjans A; Paelinck BP; Marchau F; Gunning B; Gammaitoni A; Galer BS; Lagae L; Ceulemans B
    Eur J Neurol; 2017 Feb; 24(2):309-314. PubMed ID: 27790834
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fenfluramine increases survival and reduces markers of neurodegeneration in a mouse model of Dravet syndrome.
    Cha J; Filatov G; Smith SJ; Gammaitoni AR; Lothe A; Reeder T
    Epilepsia Open; 2024 Feb; 9(1):300-313. PubMed ID: 38018342
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent advances in pharmacotherapy for epilepsy.
    Pong AW; Xu KJ; Klein P
    Curr Opin Neurol; 2023 Apr; 36(2):77-85. PubMed ID: 36762638
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of new medical treatments for the management of developmental and epileptic encephalopathies: Novel concepts and results.
    Johannessen Landmark C; Potschka H; Auvin S; Wilmshurst JM; Johannessen SI; Kasteleijn-Nolst Trenité D; Wirrell EC
    Epilepsia; 2021 Apr; 62(4):857-873. PubMed ID: 33638459
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An Emerging Role for Sigma-1 Receptors in the Treatment of Developmental and Epileptic Encephalopathies.
    Martin P; Reeder T; Sourbron J; de Witte PAM; Gammaitoni AR; Galer BS
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445144
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Caregivers' Perspectives on the Impact of Cannabidiol (CBD) Treatment for Dravet and Lennox-Gastaut Syndromes: A Multinational Qualitative Study.
    Marshall J; Skrobanski H; Moore-Ramdin L; Kornalska K; Swinburn P; Bowditch S
    J Child Neurol; 2023 May; 38(6-7):394-406. PubMed ID: 37455396
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.
    Gunning B; Mazurkiewicz-Bełdzińska M; Chin RFM; Bhathal H; Nortvedt C; Dunayevich E; Checketts D
    Acta Neurol Scand; 2021 Feb; 143(2):154-163. PubMed ID: 32969022
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Individualized treatment approaches: Fenfluramine, a novel antiepileptic medication for the treatment of seizures in Dravet syndrome.
    Polster T
    Epilepsy Behav; 2019 Feb; 91():99-102. PubMed ID: 30269941
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
    Talwar A; Estes E; Aparasu R; Reddy DS
    Exp Neurol; 2023 Jan; 359():114238. PubMed ID: 36206805
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS
    Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of cannabinoids in epilepsy treatment: a critical review of efficacy results from clinical trials.
    Nabbout R; Thiele EA
    Epileptic Disord; 2020 Jan; 22(S1):23-28. PubMed ID: 31916540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.